Camilla Sandberg
Chief Executive Officer bij MIRIS HOLDING AB
Profiel
Camilla Myhre Sandberg is currently the Chief Executive Officer at Miris Holding AB since 2016.
She is also an Independent Director at Monivent AB and NextCell Pharma AB.
Previously, she worked as the Vice President-Sales & Marketing at BioLamina AB.
Ms. Sandberg completed her undergraduate degree in 1996 and MBA in 1998 from the University of Oslo.
Actieve functies van Camilla Sandberg
| Bedrijven | Functie | Begin |
|---|---|---|
| MIRIS HOLDING AB | Chief Executive Officer | 04-10-2016 |
| NEXTCELL PHARMA AB | Director/Board Member | 01-01-2017 |
| MONIVENT AB | Director/Board Member | - |
Eerdere bekende functies van Camilla Sandberg
| Bedrijven | Functie | Einde |
|---|---|---|
BioLamina AB
 BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Sales & Marketing | - |
Opleiding van Camilla Sandberg
| University of Oslo | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MIRIS HOLDING AB | Electronic Technology |
| MONIVENT AB | Health Technology |
| NEXTCELL PHARMA AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
BioLamina AB
BioLamina AB BiotechnologyHealth Technology BioLamina AB develops, manufactures and markets cell culture reagents intended for culturing of primary cells. Its applications animal stem cells, cancer cells, cardiac applications, clonal applications, endothelial applications, epithelial applications, expansion of human PSC, eye applications, hepatic applications, intestinal applications, kidney cell culture, lung applications, neural applications, pancreatic applications and skeletal muscle applications. The company was founded by Kristian Tryggvason and Karl Tryggvason in 2008 and is headquartered in Sundbyberg, Sweden. | Health Technology |
